KR-31761, a Novel K+ATP-Channel Opener, exerts cardioprotective effects by opening both mitochondrial k+atp and sarcolemmal k+atp channels in rat models of ischemia/reperfusion-induced heart injury

Journal of Pharmacological Sciences

Volumn 109, Issue 2, 2009, Pages 222-232

  Yang, Min Kyu ^a   Lee, Sung Hun ^a   Seo, Ho Won ^b   Yi, Kyu Yang ^b   Yoo, Sung Eun ^b   Lee, Byung Ho ^b   Chung, Hun Jong ^a   Won, Hyung Sik ^a   Lee, Chang Soo ^a   Kwon, Suk Hyung ^c   Choi, Wahn Soo ^a   Shin, Hwa Sup ^a  

^a Konkuk University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Rexgene Biotech Co Ltd   (South Korea)

Author keywords

Cardioprotection; Ischemia reperfusion; Katp; KR 31761; Rat heart

Indexed keywords

5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE; CLAMIKALANT; GLIBENCLAMIDE; KR 31761; LACTATE DEHYDROGENASE; METHOXAMINE; N (4 CHLOROPHENYL) N' CYANO N'' (6 CYANO 3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 2H 1 BENZOPYRAN 4 YL)GUANIDINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BENZOPYRAN DERIVATIVE; CARDIOTONIC AGENT; INDOLE DERIVATIVE; KR-31761; MITOCHONDRIAL K(ATP) CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HEART INFARCTION; HEART INFARCTION SIZE; HEART INJURY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; RAT; ANIMAL; DISEASE MODEL; DRUG POTENTIATION; HEART MITOCHONDRION; IN VITRO STUDY; REPERFUSION INJURY; SARCOLEMMA; SPRAGUE DAWLEY RAT; VASODILATATION;

ANIMALS; BENZOPYRANS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; INDOLES; KATP CHANNELS; MALE; MITOCHONDRIA, HEART; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SARCOLEMMA; VASODILATION;

EID: 65449118394     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08132FP     Document Type: Article

References (54)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136.
2. Li L, Watanabe Y, Matsuoka I, Kimura J. Acidic preconditioning inhibits Na+/H+ and Na+/Ca2+ exchanger interaction via PKCepsilon in guinea-pig ventricular myocytes. J Pharmacol Sci. 2008;107:309-316.
3. Wang Y, Haider HK, Ahmad N, Ashraf M. Mechanisms by which Katp channel openers produce acute and delayed cardio- protection. Vascul Pharmacol. 2005;42:253-264.
4. Szewczyk A, Czyz A, Wojcik G, Wojtczak L, Nalecz MJ. ATP- regulated K+ channel in mitochondria: pharmacology and function. J Bioenerg Biomembr. 1996;28:147-152.
5. O'Rourke B. Myocardial KATP channels in preconditioning. Circ Res. 2000;87:845-855.
6. Gross GJ, Peart JN. KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol. 2003;285: H921-H930.
7. Grover GJ, D'Alonzo AJ, Garlid KD, Bajgar R, Lodge NJ, Sleph PG, et al. Pharmacologic characterization of BMS-191095, a mitochondrial Katp opener with no peripheral vasodilator or cardiac action potential shortening activity. J Pharmacol Exp Ther. 2001;297:1184-1192.
8. Teshima Y, Akao M, Li RA, Chong TH, Baumgartner WA, Johnston MV, et al. Mitochondrial ATP-sensitive potassium channel activation protects cerebellar granule neurons from apoptosis induced by oxidative stress. Stroke. 2003;34:1796-1802. (Pubitemid 36842648)
9. Armstrong SC, Liu GS, Downey JM, Ganote CE. Potassium channels and preconditioning of isolated rabbit cardiomyocytes: effects of glyburide and pinacidil. J Mol Cell Cardiol. 1995; 27:1765-1774.
10. Mizumura T, Nithipatikom K, Gross GJ. Bimakalim, an ATP- sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Circulation. 1995;92: 1236-1245.
11. Yao Z, Gross GJ. The ATP-dependent potassium channel: an endogenous cardioprotective mechanism. J Cardiovasc Pharmacol. 1994;24:S28-S34.
12. Atwal KS. Pharmacology and structure-activity relationships for Katp modulators: tissue-selective Katp openers. J Cardiovasc Pharmacol. 1994;24:S12-S17.
13. Rohmann S, Fuchs C, Schelling P. In swine myocardium, the infarct size reduction induced by U-89232 is glibenclamide sensitive: evidence that U-89232 is a cardioselective opener of ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1997;29:69-74.
14. Grover GJ, D'Alonzo AJ, Hess T, Sleph PG, Darbenzio RB. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening. Cardiovasc Res. 1995;30:731-738.
15. Minamiyama Y, Takemura S, Hai S, Suehiro S, Okada S, Funae Y. Nicorandil elevates tissue cGMP levels in a nitric-oxide- independent manner. J Pharmacol Sci. 2007;103:33-39.
16. Lee BH, Seo HW, Yoo SE, Kim SO, Lim H, Shin HS. Differential action of KR-31378, a novel potassium channel activator, on cardioprotective and hemodynamic effects. Drug Devel Res. 2001;54:182-190.
17. Hwang GS, Oh KS, Koo HN, Seo HW, You KH, Lee BH. Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure. Eur J Pharmacol. 2006;540:131-138.
18. Rovnyak GC, Ahmed SZ, Ding CZ, Dzwonczyk S, Ferrara FN, Humphreys WG, et al. Cardioselective antiischemic ATP- sensitive potassium channel (Katp) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. J Med Chem. 1997;40:24-34.
19. Ding CZ, Rovnyak GC, Misra RN, Grover GJ, Mille, AV, Ahmed SZ, et al. Cardioselective antiischemic ATP-sensitive potassium channel (Katp) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines. J Med Chem. 1999;42: 3711-3717.
20. Coghlan MJ, Carroll WA, Gopalakrishnan M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J Med Chem. 2001;44:1627-1653.
21. Mayanagi K, Gaspar T, Katakam PV, Kis B, Busija DW. The mitochondrial KATP channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2007;27:348-355.
22. Kis B, Nagy K, Snipes JA, Rajapakse NC, Horiguchi T, Grover GJ, et al. The mitochondrial KATP channel opener BMS-191095 induces neuronal preconditioning. Neuroreport. 2004;15:345-349. (Pubitemid 38297363)
23. Kim SO, Cho IS, Gu HK, Lee DH, Lim H, Yoo SE. KR-31378 protects neurons from ischemia-reperfusion brain injury by attenuating lipid peroxidation and glutathione loss. Eur J Pharmacol. 2004;487:81-91.
24. Won R, Lim JY, Lee SY, Park JH, Sohn NW. Neuroprotective effect of KR-31378 via KATP channel opening against ischemic insult. Biol Pharm Bull. 2004;27:1285-1288.
25. Lee CH, Choi KY, Kim YJ, Kim WG. Neuroprotective effect of KR-31378, a novel potassium channel activator, on spinal cord ischemic injury in rabbits. J Invest Surg. 2005;18:297-304.
26. Wang Y, Ahmad N, Wang B, Ashraf M. Chronic preconditioning: a novel approach for cardiac protection. Am J Physiol Heart Circ Physiol. 2007;292:H2300-H2305.
27. Lee SH, Yang MK, Lim JH, Seo HW, Yi KY, Yoo SE, et al. KR-31762, a novel Katp channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury. Arch Pharm Res. 2008;31:482-489.
28. Shin HS, Seo HW, Yoo SE, Lee BH. Cardiovascular pharmacology of SKP-450, a new potassium channel activator, and its major metabolites SKP-818 and SKP-310. Pharmacology. 1998;56:111-124.
29. Jung YS, Moon CH, Cho TS, Yoo SE, Shin HS. Cardioprotective effects of KR-30450, a novel K+ATP opener, and its major metabolite KR-30818 on isolated rat hearts. Jpn J Pharmacol. 1998;76:65-73.
30. van der Laarse A, Davids HA, Hollaar L, van der Valk EJ, Witteveen SA, Hermens WT. Recognition and quantification of myocardial injury by means of plasma enzyme and isoenzyme activities after cardiac surgery. Br Heart J. 1979;41:660-667.
31. Wroblewski F, Ladue JS. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med. 1955;90:210-213.
32. Park JW, Roh HY, Jung IS, Yun YP, Yi KY, Yoo SE, et al. Effects of [5-(2-methoxy-5-fluorophenyl)furan-2-ylcarbonyl] guanidine (KR-32560), a novel sodium/hydrogen exchanger-1 inhibitor, on myocardial infarct size and ventricular arrhythmias in a rat model of ischemia/reperfusion heart injury. J Pharmacol Sci. 2005;98:439-449.
33. Liu Y, Sato T, O'Rourke B, Marban E. Mitochondrial ATP- dependent potassium channels: novel effectors of cardioprotec- tion? Circulation. 1998;97:2463-2469. (Pubitemid 28278191)
34. Lee JH, Jung IS, Lee SH, Yang MK, Hwang JH, Lee HD, et al. Cardioprotective effects of BMS-180448, a prototype mitoKatp channel opener, and the role of salvage kinases, in the rat model of global ischemia and reperfusion heart injury. Arch Pharm Res. 2007;30:634-640.
35. Gomoll AW, Roth RA, Swillo RE, Baird AJ, Sargent CS, Behling RW, et al. Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448. J Pharmacol Exp Ther. 1997;281:24-33. (Pubitemid 27203047)
36. Park YS, Yoo SE, Shin HS, Jin YR, Yun YP. Pharmacological characterization of vasorelaxant effects of BMS-180448, a novel cardioselective ATP-sensitive potassium channel opener, in rat aorta. J Pharmacol Sci. 2003;92:218-227.
37. Grover GJ, Atwal KS. Pharmacologic profile of the selective mitochondrial-KATP opener BMS-191095 for treatment of acute myocardial ischemia. Cardiovasc Drug Rev. 2002;20:121-136.
38. Ghosh S, Standen NB, Galinanes M. Evidence for mitochondrial Katp channels as effectors of human myocardial preconditioning. Cardiovasc Res. 2000;45:934-940.
39. Cole WC, McPherson CD, Sontag D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res. 1991;69:571-581.
40. D'Alonzo AJ, Darbenzio RB, Parham CS, Grover GJ. Effects of intracoronary cromakalim on postischaemic contractile function and action potential duration. Cardiovasc Res. 1992;26:1046-1053.
41. Burwell LS, Brookes PS. Mitochondria as a target for the cardioprotective effects of nitric oxide in ischemia-reperfusion injury. Antioxid Redox Signal. 2008;10:579-599.
42. Gross ER, Hsu AK, Gross GJ. Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion. Am J Physiol Heart Circ Physiol. 2008;294:H1497-H1500.
43. Matejikova J, Kucharska J, Pinterova M, Pancza D, Ravingerova T. Protection against ischaemia-induced ventricular arrhythmias and myocardial dysfunction conferred by preconditioning in the rat heart: Involvement of mitochondrial Katp channels and reactive oxygen species. Physiol Res. in press
44. Billman GE. The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy. Pharmacol Ther. 2008;120:54-70.
45. Costa AD, Pierre SV, Cohen MV, Downey JM, Garlid KD. cGMP signalling in pre- and post-conditioning: the role of mitochondria. Cardiovasc Res. 2008;77:344-352.
46. Mozaffari MS, Schaffer SW. Effect of pressure overload on cardioprotection of mitochondrial KATP channels and GSK- 3beta: interaction with the MPT pore. Am J Hypertens. 2008;21:570-575.
47. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 1999;399:483-487.
48. Kis B, Rajapakse NC, Snipes JA, Nagy K, Horiguchi T, Busija DW. Diazoxide induces delayed pre-conditioning in cultured rat cortical neurons. J Neurochem. 2003;87:969-980.
49. Minners J, Lacerda L, Yellon DM, Opie LH, McLeod CJ, Sack MN. Diazoxide-induced respiratory inhibition - a putative mito- chondrial Katp channel independent mechanism of pharmacological preconditioning. Mol Cell Biochem. 2007;294:11-18.
50. Andrukhiv A, Costa AD, West IC, Garlid KD. Opening mitoKATP increases superoxide generation from complex I of the electron transport chain. Am J Physiol Heart Circ Physiol. 2006;291:H2067-H2074.
51. Khan SA, Higdon NR, Hester JB, Meisheri KD. Pharmacological characterization of novel cyanoguanidines as vascular Katp channel blockers. J Pharmacol Exp Ther. 1997;283:1207-1213.
52. Quast U, Cook NS. Moving together: K+ channel openers and ATP-sensitive K+ channels. Trends Pharmacol Sci. 1990;10: 431-435.
53. Cui Y, Tinker A, Clapp LH. Different molecular sites of action for the Katp channel inhibitors, PNU-99963 and PNU-37883A. Br J Pharmacol. 2003;139:122-128. (Pubitemid 36645315)
54. Lacza Z, Snipes JA, Miller AW, Szabo C, Grover G, Busija DW. Heart mitochondria contain functional ATP-dependent K+ channels. J Mol Cell Cardiol. 2003;35:1339-1347.